{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:21:54Z","timestamp":1740108114541,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Behandlung von Patienten mit Demenz mit Lewy-K\u00f6rpern (DLK) ist vielschichtig, da motorische Symptome, kognitive Symptome und Verhaltens- und psychische Symptome in unterschiedlichen Konstellationen auftreten k\u00f6nnen. Zudem ist der Einsatz bestimmter Medikamente nur bedingt m\u00f6glich (z.\u202fB. Neuroleptika).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>In diesem \u00dcbersichtsartikel sollen die wichtigsten neuen Erkenntnisse zur Behandlung der DLK zusammengetragen werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Bisher existiert in Deutschland keine zugelassene Therapieoption f\u00fcr die Behandlung der Patienten mit DLK; die Evidenzbasis f\u00fcr die pharmakologischen und nichtpharmakologischen Behandlungsoptionen ist zudem d\u00fcrftig. Die derzeit konsentierten Therapieans\u00e4tze st\u00fctzen sich auf die Behandlung der motorischen Symptome in Anlehnung an die Therapie bei der Parkinson-Krankheit und bei den Verhaltenssymptomen an die Therapie der Alzheimer-Krankheit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die Behandlung der DLK mit ihren verschiedenartigen Symptomen ist schwierig und oftmals erst in enger fach\u00e4rztlicher Zusammenarbeit ad\u00e4quat f\u00fcr den Patienten zu erreichen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00115-023-01577-2","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T15:02:36Z","timestamp":1702566156000},"page":"362-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Demenz mit Lewy-K\u00f6rpern: alte und neue Erkenntnisse \u2013 Teil\u00a02: Behandlung","Dementia with Lewy bodies: old and new knowledge\u2014Part 2: treatment"],"prefix":"10.1007","volume":"95","author":[{"given":"Richard","family":"Dodel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Kalbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"5","key":"1577_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland\u00a0D, Ballard\u00a0C, Larsen\u00a0JP, McKeith\u00a0I (2001) A\u00a0comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry 16(5):528\u2013536","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"1577_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0891988720988916","volume":"35","author":"K Badwal","year":"2022","unstructured":"Badwal\u00a0K, Kiliaki\u00a0SA, Dugani\u00a0SB, Pagali\u00a0SR (2022) Psychosis management in Lewy body dementia: a\u00a0comprehensive clinical approach. J\u00a0Geriatr Psychiatry Neurol 35(3):255\u2013261","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"2","key":"1577_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1212\/01.WNL.0000130194.84594.96","volume":"63","author":"SB Bonelli","year":"2004","unstructured":"Bonelli\u00a0SB, Ransmayr\u00a0G, Steffelbauer\u00a0M et al (2004) L\u2011dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 63(2):376\u2013378","journal-title":"Neurology"},{"issue":"1","key":"1577_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.archger.2007.03.003","volume":"46","author":"B Borroni","year":"2008","unstructured":"Borroni\u00a0B, Agosti\u00a0C, Padovani\u00a0A (2008) Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 46(1):101\u2013106","journal-title":"Arch Gerontol Geriatr"},{"issue":"4)","key":"1577_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/WAD.0b013e3181e6a4d7","volume":"24","author":"S Culo","year":"2010","unstructured":"Culo\u00a0S, Mulsant\u00a0BH, Rosen\u00a0J et al (2010) Treating neuropsychiatric symptoms in dementia with Lewy bodies: a\u00a0randomized controlled-trial. Alzheimer Dis Assoc Disord 24(4)):360\u2013364","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1577_CR6","unstructured":"DGN e. V. & DGPPN e. V. (Hrsg.) S3-Leitlinie Demenzen, Version 4.0, 28.11.2023. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-013. Zugegriffen: 10.12.2023"},{"key":"1577_CR7","first-page":"157","volume-title":"Parkinson-Syndrome und andere Bewegungsst\u00f6rungen","author":"R Dodel","year":"2020","unstructured":"Dodel\u00a0R, Deuschl\u00a0G (2020) Demenz mit Lewy-K\u00f6rpern. In: Oertel\u00a0W, Deuschl\u00a0G, Poewe W (Hrsg) Parkinson-Syndrome und andere Bewegungsst\u00f6rungen. Thieme, Stuttgart, S 157\u2013180"},{"issue":"6","key":"1577_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000101512","volume":"23","author":"K Edwards","year":"2007","unstructured":"Edwards\u00a0K, Royall\u00a0D, Hershey\u00a0L et al (2007) Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a\u00a024-week open-label study. Dement Geriatr Cogn Disord 23(6):401\u2013405","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"1577_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-014-0197-x","volume":"31","author":"JE Frampton","year":"2014","unstructured":"Frampton\u00a0JE (2014) Rivastigmine transdermal patch 13.3\u202fmg\/24\u202fh: a\u00a0review of its use in the management of mild to moderate Alzheimer\u2019s dementia. Drugs Aging 31(8):639\u2013649","journal-title":"Drugs Aging"},{"issue":"15","key":"1577_CR10","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"JG Goldman","year":"2008","unstructured":"Goldman\u00a0JG, Goetz\u00a0CG, Brandabur\u00a0M et al (2008) Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 23(15):2248\u20132250","journal-title":"Mov Disord"},{"issue":"1","key":"1577_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000529256","volume":"52","author":"L Guidi","year":"2023","unstructured":"Guidi\u00a0L, Evangelisti\u00a0S, Siniscalco\u00a0A et al (2023) Non-pharmacological treatments in Lewy body disease: a\u00a0systematic review. Dement Geriatr Cogn Disord 52(1):16\u201331","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"1577_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"LA Hershey","year":"2019","unstructured":"Hershey\u00a0LA, Coleman-Jackson\u00a0R (2019) Pharmacological management of dementia with Lewy bodies. Drugs Aging 36(4):309\u2013319","journal-title":"Drugs Aging"},{"key":"1577_CR13","unstructured":"H\u00f6glinger G, Trenkwalder C et al (2023) Parkinson-Krankheit, S2k-Leitlinie, 2023. In Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien. Zugegriffen: 10.12.2023"},{"issue":"1","key":"1577_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda\u00a0M, Mori\u00a0E, Matsuo\u00a0K et al (2015) Donepezil for dementia with Lewy bodies: a\u00a0randomized, placebo-controlled, confirmatory phase\u00a0III trial. Alzheimers Res Ther 7(1):4","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"1577_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","volume":"38","author":"IV Litvinenko","year":"2008","unstructured":"Litvinenko\u00a0IV, Odinak\u00a0MM, Mogil\u2019naya\u00a0VI et al (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson\u2019s disease (an open controlled trial). Neurosci Behav Physiol 38(9):937\u2013945","journal-title":"Neurosci Behav Physiol"},{"issue":"4","key":"1577_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jagp.2013.11.007","volume":"23","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga\u00a0S, Kishi\u00a0T, Iwata\u00a0N (2015) Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry 23(4):373\u2013383","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6855","key":"1577_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/bmj.305.6855.673","volume":"305","author":"I McKeith","year":"1992","unstructured":"McKeith\u00a0I, Fairbairn\u00a0A, Perry\u00a0R et al (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305(6855):673\u2013678","journal-title":"BMJ"},{"issue":"3","key":"1577_CR18","first-page":"1611","volume":"17","author":"YH Meng","year":"2019","unstructured":"Meng\u00a0YH, Wang\u00a0PP, Song\u00a0YX et al (2019) Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: a\u00a0meta-analysis. Exp Ther Med 17(3):1611\u20131624","journal-title":"Exp Ther Med"},{"issue":"11","key":"1577_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"J Mintzer","year":"2021","unstructured":"Mintzer\u00a0J, Lanctot\u00a0KL, Scherer\u00a0RW et\u00a0al (2021) Effect of Methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol 78(11):1324\u20131332","journal-title":"JAMA Neurol"},{"issue":"1","key":"1577_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori\u00a0E, Ikeda\u00a0M, Kosaka\u00a0K, Donepezil\u00a0DLBSI (2012) Donepezil for dementia with Lewy bodies: a\u00a0randomized, placebo-controlled trial. Ann Neurol 72(1):41\u201352","journal-title":"Ann Neurol"},{"issue":"3\u20134","key":"1577_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000433524","volume":"40","author":"E Mori","year":"2015","unstructured":"Mori\u00a0E, Ikeda\u00a0M, Nakagawa\u00a0M et al (2015) Effects of Donepezil on extrapyramidal symptoms in patients with dementia with Lewy bodies: a\u00a0secondary pooled analysis of two randomized-controlled and two open-label long-term extension studies. Dement Geriatr Cogn Disord 40(3\u20134):186\u2013198","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"1577_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1017\/S1041610217002010","volume":"30","author":"H Morrin","year":"2018","unstructured":"Morrin\u00a0H, Fang\u00a0T, Servant\u00a0D et al (2018) Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. Int Psychogeriatr 30(3):395\u2013407","journal-title":"Int Psychogeriatr"},{"issue":"7","key":"1577_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/00001756-199403000-00002","volume":"5","author":"EK Perry","year":"1994","unstructured":"Perry\u00a0EK, Haroutunian\u00a0V, Davis\u00a0KL et\u00a0al (1994) Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer\u2019s disease. Neuroreport 5(7):747\u2013749","journal-title":"Neuroreport"},{"issue":"7","key":"1577_CR24","doi-asserted-by":"publisher","first-page":"e005158","DOI":"10.1136\/bmjopen-2014-005158","volume":"4","author":"K Stubendorff","year":"2014","unstructured":"Stubendorff\u00a0K, Larsson\u00a0V, Ballard\u00a0C et\u00a0al (2014) Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: a\u00a0prospective study. BMJ Open 4(7):e5158","journal-title":"BMJ Open"},{"key":"1577_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/DDDT.S240865","volume":"15","author":"B Tousi","year":"2021","unstructured":"Tousi\u00a0B, Leverenz\u00a0JB (2021) The application of Zonisamide to patients suffering from dementia with Lewy bodies: emerging clinical data. Drug Des Devel Ther 15:1811\u20131817","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"1577_CR26","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1176\/appi.ajp.2007.07040715","volume":"164","author":"D Weintraub","year":"2007","unstructured":"Weintraub\u00a0D, Hurtig\u00a0HI (2007) Presentation and management of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies. Am J Psychiatry 164(10):1491\u20131498","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1577_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/gps.4109","volume":"30","author":"KA Wesnes","year":"2015","unstructured":"Wesnes\u00a0KA, Aarsland\u00a0D, Ballard\u00a0C et al (2015) Memantine improves attention and episodic memory in Parkinson\u2019s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 30(1):46\u201354","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1577_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12877-018-0740-4","volume":"18","author":"I Zahirovic","year":"2018","unstructured":"Zahirovic\u00a0I, Torisson\u00a0G, Wattmo\u00a0C et al (2018) Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a\u00a0cross-sectional study in 40 nursing homes in Sweden. BMC Geriatr 18(1):50","journal-title":"BMC Geriatr"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01577-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:02:20Z","timestamp":1712919740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01577-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01577-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"26 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Dodel, D.\u00a0Berg, T.\u00a0Duning, E.\u00a0Kalbe, P.T.\u00a0Meyer, A.\u00a0Ramirez, A.\u00a0Storch, D.\u00a0Aarsland und F.\u00a0Jessen geben an, dass kein Interessenkonflikt bez\u00fcglich des Inhalts des Artikels besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}